{"id":10746,"date":"2020-08-31T11:52:42","date_gmt":"2020-08-31T09:52:42","guid":{"rendered":"https:\/\/www.ship2b.org\/?p=10746"},"modified":"2025-02-08T01:13:38","modified_gmt":"2025-02-08T00:13:38","slug":"admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer","status":"publish","type":"post","link":"https:\/\/www.ship2b.org\/en\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/","title":{"rendered":"ADmit Therapeutics consigue 4,2 millones para desarrollar un test de detecci\u00f3n precoz del Alzheimer"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.admit-therapeutics.com\/es\" target=\"_blank\" rel=\"noopener noreferrer\">ADmit Therapeutics<\/a><\/strong>, startup que desarrolla un <strong>test para la detecci\u00f3n precoz del Alzheimer,<\/strong> consigue cerrar una<strong> ronda de financiaci\u00f3n de 785.000 euros<\/strong>, liderada por nuestro veh\u00edculo de inversi\u00f3n <strong>Equity4Good<\/strong> -que cuenta con el apoyo del Fondo Europeo de Inversi\u00f3n&#8211;, que ha realizado un follow-on en esta operaci\u00f3n, y un <strong>agente clave del sector<\/strong>. Parte de la ronda se ha realizado a trav\u00e9s de <a href=\"https:\/\/capitalcell.es\/campaign\/admit\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>Capital Cell<\/strong><\/a> y a ella se suman <strong>3,4 millones de euros del EIC Accelerator<\/strong>, instrumento del Consejo Europeo de Innovaci\u00f3n que ofrece un modelo mixto de inversi\u00f3n de capital y subvenci\u00f3n para ayudar a las startups a escalar de manera m\u00e1s r\u00e1pida y efectiva.<\/p>\n<p>ADmit Therapeutics es una<strong> spin-off del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge<\/strong> (IDIBELL) creada a finales de 2017 y alumni de nuestro <strong>programa de aceleraci\u00f3n e inversi\u00f3n <a href=\"https:\/\/www.ship2b.org\/programa\/s2b-healthandcare-aceleramos-invertimos-startups\" target=\"_blank\" rel=\"noopener noreferrer\">Health&amp;Care<\/a><\/strong>. Est\u00e1 centrada en el desarrollo de un test de diagn\u00f3stico precoz para la enfermedad de Alzheimer basado en un an\u00e1lisis de sangre. La financiaci\u00f3n conseguida se destinar\u00e1 a completar la prueba de concepto cl\u00ednica para iniciar la validaci\u00f3n cl\u00ednica en 2021 y obtener el marcado CE en 2023.<\/p>\n<h3><strong>Diagn\u00f3stico precoz<\/strong><\/h3>\n<p>&#8220;Nuestro principal objetivo es desarrollar una prueba de diagn\u00f3stico precoz de Alzheimer e implementarla en la pr\u00e1ctica cl\u00ednica. A corto plazo el <strong>test de diagn\u00f3stico permitir\u00eda optimizar el reclutamiento de los pacientes en los ensayos cl\u00ednicos<\/strong>, de tal manera que se incrementar\u00eda la posibilidad de identificar un f\u00e1rmaco curativo para esta enfermedad al poder demostrarse su eficacia\u201d explica <strong>Marta Barrachina, directora general y cofundadora de la empresa<\/strong>. Barrachina es Doctora en Bioqu\u00edmica y MBA y es la investigadora principal en IDIBELL desde el 2006. Ha liderado proyectos competitivos p\u00fablicos y privados, y es la inventora de seis patentes. Los <strong>m\u00e9dicos Ramon Re\u00f1\u00e9 y Jordi Gasc\u00f3n son los otros cofundadores de ADmit Therapeutics<\/strong> y act\u00faan como Consejo Asesor M\u00e9dico de la empresa liderando el estudio cl\u00ednico.<\/p>\n<p>El Alzheimer es una necesidad m\u00e9dica no cubierta. \u201c<strong>No existe un f\u00e1rmaco curativo dado que los ensayos cl\u00ednicos han presentado una tasa de \u00e9xito del 0,4%, la m\u00e1s baja de todas las enfermedades graves de gran prevalencia<\/strong>\u201d, explica Barrachina. Actualmente existe un infradiagn\u00f3stico de la enfermedad y se acostumbra a realizar en la fase moderada con un retraso de entre 12 y 24 meses una vez han aparecido los s\u00edntomas. \u201cEl problema radica en que la enfermedad presenta un <strong>periodo asintom\u00e1tico que puede durar hasta 20 a\u00f1os<\/strong>\u201d, remarca la doctora.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ADmit Therapeutics, startup que desarrolla un test para la detecci\u00f3n precoz del Alzheimer, consigue cerrar una ronda de financiaci\u00f3n de 785.000 euros, liderada por nuestro veh\u00edculo de inversi\u00f3n Equity4Good -que cuenta con el apoyo del Fondo Europeo de Inversi\u00f3n&#8211;, que ha realizado un follow-on en esta operaci\u00f3n, y un agente clave del sector. Parte de &hellip; <a href=\"https:\/\/www.ship2b.org\/en\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/\">Read more<\/a><\/p>\n","protected":false},"author":3,"featured_media":10748,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[21,23],"tags":[187,287],"class_list":["post-10746","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ship2b","category-inversion-de-impacto","tag-equity4good","tag-admit-therapeutics"],"acf":[],"yoast_head":"<title>ADmit consigue 4,2 millones para Test de Detecci\u00f3n Alzheimer | Ship2B<\/title>\n<meta name=\"description\" content=\"ADmit, startup que desarrolla un test para la detecci\u00f3n precoz del Alzheimer, cierra ronda de financiaci\u00f3n de 785.000 euros, liderada por Equity4Good.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADmit consigue 4,2 millones para Test de Detecci\u00f3n Alzheimer | Ship2B\" \/>\n<meta property=\"og:description\" content=\"ADmit, startup que desarrolla un test para la detecci\u00f3n precoz del Alzheimer, cierra ronda de financiaci\u00f3n de 785.000 euros, liderada por Equity4Good.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"Ship2B Foundation\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-31T09:52:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-08T00:13:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/08\/ADmit_Therapeutics.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/\",\"url\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/\",\"name\":\"ADmit consigue 4,2 millones para Test de Detecci\u00f3n Alzheimer | Ship2B\",\"isPartOf\":{\"@id\":\"https:\/\/www.ship2b.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/08\/ADmit_Therapeutics.jpg\",\"datePublished\":\"2020-08-31T09:52:42+00:00\",\"dateModified\":\"2025-02-08T00:13:38+00:00\",\"author\":{\"@id\":\"\"},\"description\":\"ADmit, startup que desarrolla un test para la detecci\u00f3n precoz del Alzheimer, cierra ronda de financiaci\u00f3n de 785.000 euros, liderada por Equity4Good.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/#primaryimage\",\"url\":\"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/08\/ADmit_Therapeutics.jpg\",\"contentUrl\":\"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/08\/ADmit_Therapeutics.jpg\",\"width\":800,\"height\":400,\"caption\":\"ADmit Therapeutics Test Alzheimer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/www.ship2b.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADmit Therapeutics consigue 4,2 millones para desarrollar un test de detecci\u00f3n precoz del Alzheimer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ship2b.org\/#website\",\"url\":\"https:\/\/www.ship2b.org\/\",\"name\":\"Ship2B Foundation\",\"description\":\"Adventurers for a better world\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ship2b.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\/\/www.ship2b.org\/en\/actualidad\/author\/\"}]}<\/script>","yoast_head_json":{"title":"ADmit consigue 4,2 millones para Test de Detecci\u00f3n Alzheimer | Ship2B","description":"ADmit, startup que desarrolla un test para la detecci\u00f3n precoz del Alzheimer, cierra ronda de financiaci\u00f3n de 785.000 euros, liderada por Equity4Good.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/","og_locale":"en_US","og_type":"article","og_title":"ADmit consigue 4,2 millones para Test de Detecci\u00f3n Alzheimer | Ship2B","og_description":"ADmit, startup que desarrolla un test para la detecci\u00f3n precoz del Alzheimer, cierra ronda de financiaci\u00f3n de 785.000 euros, liderada por Equity4Good.","og_url":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/","og_site_name":"Ship2B Foundation","article_published_time":"2020-08-31T09:52:42+00:00","article_modified_time":"2025-02-08T00:13:38+00:00","og_image":[{"width":800,"height":400,"url":"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/08\/ADmit_Therapeutics.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Written by":"","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/","url":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/","name":"ADmit consigue 4,2 millones para Test de Detecci\u00f3n Alzheimer | Ship2B","isPartOf":{"@id":"https:\/\/www.ship2b.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/#primaryimage"},"image":{"@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/08\/ADmit_Therapeutics.jpg","datePublished":"2020-08-31T09:52:42+00:00","dateModified":"2025-02-08T00:13:38+00:00","author":{"@id":""},"description":"ADmit, startup que desarrolla un test para la detecci\u00f3n precoz del Alzheimer, cierra ronda de financiaci\u00f3n de 785.000 euros, liderada por Equity4Good.","breadcrumb":{"@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/#primaryimage","url":"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/08\/ADmit_Therapeutics.jpg","contentUrl":"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/08\/ADmit_Therapeutics.jpg","width":800,"height":400,"caption":"ADmit Therapeutics Test Alzheimer"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-consigue-42-millones-para-desarrollar-un-test-de-deteccion-precoz-del-alzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.ship2b.org\/en\/"},{"@type":"ListItem","position":2,"name":"ADmit Therapeutics consigue 4,2 millones para desarrollar un test de detecci\u00f3n precoz del Alzheimer"}]},{"@type":"WebSite","@id":"https:\/\/www.ship2b.org\/#website","url":"https:\/\/www.ship2b.org\/","name":"Ship2B Foundation","description":"Adventurers for a better world","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ship2b.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"","url":"https:\/\/www.ship2b.org\/en\/actualidad\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts\/10746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/comments?post=10746"}],"version-history":[{"count":2,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts\/10746\/revisions"}],"predecessor-version":[{"id":11191,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts\/10746\/revisions\/11191"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/media\/10748"}],"wp:attachment":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/media?parent=10746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/categories?post=10746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/tags?post=10746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}